Category Archives: Drug Shortages

Gentamicin Sulfate Injection

Presentation

80 mg per 2 mL (40 mg per mL), MDV, (NDC 63323-010-02)

800 mg per 20 mL (40 mg per mL), MDV, (NDC 63323-010-20)

20 mg per 2 mL (10 mg per mL), Pediatric SDV, (NDC 63323-173-02)

Availability and Estimated Shortage Duration

Backordered. Next release May 2022.

Backordered. Next release May 2022.

Related Information

Check wholesaler inventory

Shortage Reason (per FDASIA)

Manufacturing delay

US-FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Gentamicin+Sulfate+Injection&st=c&tab=tabs-4&panels=1

Furosemide Injection

Presentation

20 mg/2mL vial (NDC 70860-302-41 and 70860-302-02)

40 mg/4mL vial (NDC 70860-302-42 and 70860-302-04)

100 mg/10mL vial (NDC 70860-302-43 and 70860-302-10)

Availability and Estimated Shortage Duration

Available

Related Information

Marketed by Athenex. To order, contact Athenex at 855-273-0154

Shortage Reason (per FDASIA)

US-FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide+Injection&st=c&tab=tabs-4&panels=1

Fentanyl Citrate (Sublimaze) Injection

Presentation:

2 mL ampule 10 pack (NDC 17478-0030-02)\

2 mL ampule; 25 pack (NDC 17478-0030-25)

5 mL ampule 10 pack (NDC 17478-0030-05)

20 mL ampule (NDC 17478-0030-20)

5 mL ampule 25 pack (NDC 17478-0030-55)

Availability and Estimated Shortage Duration

Available

Discontinued

Related Information

Shortage Reason (per FDASIA)

Other

 

Hydromorphone Hydrochloride Injection

Presentation:

10 mg/mL, 1 mL ampule, 10 count (NDC 17478-0540-01)

10 mg/mL, 5 mL ampule, 10 count (NDC 17478-0540-05)

10 mg/mL, 50 mL vial, 10 count (NDC 17478-0540-50)

Availability and Estimated Shortage Duration:

Available

Available

Available

Related Information:

..

Shortage Reason (per FDASIA):

Demand increase for the drug

Demand increase for the drug

US-FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Hydromorphone+Hydrochloride+Injection&st=c&tab=tabs-4&panels=1

 

CareFusion 303, Inc. Recalls BD Alaris Pump Module Model 8100 Due to Risk of Stuck or Unresponsive Keys

Date: 04/16/21

BD Alaris Infusion Pump Module

  • Affected Model Number: 8100
  • Affected Parts: 49000239; 49000346; 49000438; 49000439
  • Manufacturing Dates: 01/15/2019 to 12/05/2019.
  • Distribution Dates: January 23, 2019 to December 5, 2019
  • Devices Recalled in the U.S.: 145,492
  • Date Initiated by Firm: March 3, 2021

USA-FDA Link: https://www.fda.gov/medical-devices/medical-device-recalls/carefusion-303-inc-recalls-bd-alaris-pump-module-model-8100-due-risk-stuck-or-unresponsive-keys

Vitamin A Palmitate (Aquasol A) Injection

Presentation

50,000 USP units/mL (15 mg retinol), single dose vial (NDC 70199-0026-11)

Availability and Estimated Shortage Duration

Available

Related Information

The product will be shipping out to customers beginning 01/27/2022

Shortage Reason (per FDASIA)

 

US FDA Link:  https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Vitamin%20A%20Palmitate%20(Aquasol%20A)%20Injection&st=c&tab=tabs-1

Vecuronium Bromide for Injection

Presentation

10 mg/vial, packages of 10 (NDC 55150-235-10)

Availability and Estimated Shortage Duration

Currently on backorder, next shipment Mid March

Related Information

Sporadic availability expected.

Shortage Reason (per FDASIA)

OtherDemand increase for the drug

US FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Vecuronium%20Bromide%20for%20Injection&st=c&tab=tabs-1

Varenicline Tartrate (Chantix) Tablets

Presentation

Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5)

Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6)

Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0)

Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5)

Availability and Estimated Shortage Duration

Available

Available

Estimated Date Available; TBD

Estimated Date Available; TBD

Related Information

Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.

Shortage Reason (per FDASIA)

 

US FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Varenicline%20Tartrate%20(Chantix)%20Tablets&st=c&tab=tabs-1